PMID- 35267487
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220316
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 5
DP  - 2022 Feb 24
TI  - Epigenetics of Dendritic Cells in Tumor Immunology.
LID - 10.3390/cancers14051179 [doi]
LID - 1179
AB  - Dendritic cells (DCs) are professional antigen-presenting cells with the 
      distinctive property of inducing the priming and differentiation of naive CD4+ 
      and CD8+ T cells into helper and cytotoxic effector T cells to develop efficient 
      tumor-immune responses. DCs display pathogenic and tumorigenic antigens on their 
      surface through major histocompatibility complexes to directly influence the 
      differentiation of T cells. Cells in the tumor microenvironment (TME), including 
      cancer cells and other immune-infiltrated cells, can lead DCs to acquire an 
      immune-tolerogenic phenotype that facilitates tumor progression. Epigenetic 
      alterations contribute to cancer development, not only by directly affecting 
      cancer cells, but also by their fundamental role in the differentiation of DCs 
      that acquire a tolerogenic phenotype that, in turn, suppresses T cell-mediated 
      responses. In this review, we focus on the epigenetic regulation of DCs that have 
      infiltrated the TME and discuss how knowledge of the epigenetic control of DCs 
      can be used to improve DC-based vaccines for cancer immunotherapy.
FAU - Godoy-Tena, Gerard
AU  - Godoy-Tena G
AUID- ORCID: 0000-0003-3832-5794
AD  - Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), 
      08916 Barcelona, Spain.
FAU - Ballestar, Esteban
AU  - Ballestar E
AUID- ORCID: 0000-0002-1400-2440
AD  - Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), 
      08916 Barcelona, Spain.
AD  - Epigenetics in Inflammatory and Metabolic Diseases Laboratory, Health Science 
      Center (HSC), East China Normal University (ECNU), Shanghai 200241, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220224
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8909611
OTO - NOTNLM
OT  - DNA methylation
OT  - cancer epigenetics
OT  - dendritic cells
OT  - epigenetics
OT  - histone modification
OT  - tolerogenesis
OT  - tumor immunology
OT  - tumor microenvironment
COIS- The authors declare no conflict of interest.
EDAT- 2022/03/11 06:00
MHDA- 2022/03/11 06:01
PMCR- 2022/02/24
CRDT- 2022/03/10 15:24
PHST- 2022/01/25 00:00 [received]
PHST- 2022/02/18 00:00 [revised]
PHST- 2022/02/23 00:00 [accepted]
PHST- 2022/03/10 15:24 [entrez]
PHST- 2022/03/11 06:00 [pubmed]
PHST- 2022/03/11 06:01 [medline]
PHST- 2022/02/24 00:00 [pmc-release]
AID - cancers14051179 [pii]
AID - cancers-14-01179 [pii]
AID - 10.3390/cancers14051179 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Feb 24;14(5):1179. doi: 10.3390/cancers14051179.